Italia markets closed

JNJ Jan 2025 125.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,60000,0000 (0,00%)
Alla chiusura: 02:27PM EDT
Schermo intero
Chiusura precedente1,6000
Aperto1,6000
Denaro1,2400
Domanda1,9900
Prezzo d'esercizio125,00
Scadenza2025-01-17
Min-Max giorno1,6000 - 1,6000
Contratto - Min-MaxN/D
Volume1
Open Interest2,72k
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA